Carfilzomib in ALL



Subscribe to be notified of changes or updates to this page.

10 + 2 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.

CHOP, in collaboration with Onyx Therapeutics, Inc., is conducting a study for children and young adults up to 21 years old, with relapsed or refractory acute lymphoblastic leukemia. This clinical trial is adding the study drug, Carfilzomib, to a standard relapse chemotherapy regimen. For more information about this study, including specific eligibility criteria, please visit and search for "NCT02303821". To hear more about this and other available trails or get any questions answered please contact our Cancer Intake Specialist by phone at 267-426-0762 or email [email protected]

Who Do I Contact?

If you are interested in participating in the study or want to learn more please contact our study team at oncointake [at] or 267-426-0762.

Eligibility & Criteria

IRB #:
Official Title:
Phase 1b/2 Study Of Carfilzomib In Combination With Induction Chemotherapy In Children With Relapsed Or Refractory Acute Lymphoblastic Leukemia
Study Phase:
Phase II
Study Categories:

Visit Criteria

Participants will receive carfilzomib via intravenous (IV) infusion. Study visits will include the following assessments: blood draws; optional tissue collection (left-over or extra) will be collected if a biopsy is performed as standard of care, and optional saliva collection. Existing tissue samples may also be used in this study.